In female users of GLP-1 drugs, those rates were 5.44% with tirzepatide versus 3.63% with semaglutide, the researchers said
Lower doses can lead to fewer adverse reactions, enhancing the treatments tolerability and alleviating issues such as nausea and gastrointestinal discomfort
Studies consistently show that individuals with obesity have higher rates of alcohol use disorder, and vice versa
The dose can be increased every four weeks to a maximum of 4.5 mg weekly
Kumagae Y, Hirahashi M, Takizawa K, Yamamoto H, Gushima M, Esaki M, et al
By acting on both receptors, Tirzepatide offers a comprehensive approach to weight management that goes beyond shedding pounds